×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INMB – inmune bio inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/1
07:12 am
inmb
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study [Yahoo! Finance]
Low
Report
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study [Yahoo! Finance]
4/1
07:00 am
inmb
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
Low
Report
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
3/27
04:05 pm
inmb
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
Low
Report
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
3/24
10:58 am
inmb
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 [Yahoo! Finance]
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 [Yahoo! Finance]
3/24
08:00 am
inmb
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
2/20
08:27 am
inmb
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% [Yahoo! Finance]
Medium
Report
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% [Yahoo! Finance]
2/13
06:16 pm
inmb
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.
2/12
10:18 am
inmb
INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]
Low
Report
INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
04:05 pm
inmb
inmune bio inc. - common stock
MISS
Report
3.2%
inmune bio inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
04:02 pm
inmb
Form 8-K Inmune Bio, Inc. For: Apr 01
Medium
Report
Form 8-K Inmune Bio, Inc. For: Apr 01
3/27
04:30 pm
inmb
Form 8-K Inmune Bio, Inc. For: Mar 27
Medium
Report
Form 8-K Inmune Bio, Inc. For: Mar 27
3/27
04:07 pm
inmb
Form 10-K Inmune Bio, Inc. For: Dec 31
Low
Report
Form 10-K Inmune Bio, Inc. For: Dec 31
3/24
10:28 am
inmb
Form 8-K Inmune Bio, Inc. For: Mar 24
Low
Report
Form 8-K Inmune Bio, Inc. For: Mar 24
3/4
02:21 pm
inmb
Form 8-K Inmune Bio, Inc. For: Mar 04
Low
Report
Form 8-K Inmune Bio, Inc. For: Mar 04
2/12
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Feb 12
Low
Report
Form 8-K Inmune Bio, Inc. For: Feb 12
2/10
04:00 pm
inmb
Form 8-K Inmune Bio, Inc. For: Feb 06
Medium
Report
Form 8-K Inmune Bio, Inc. For: Feb 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/11
Form 10-K Inmune Bio, Inc. For: Dec 31
26.3%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
TOP News Decliners
3/11
INmune Bio Inc. (INMB) CEO R.J. Tesi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: